Chemical industry is the company's second largest industry. The company produces 358 kinds of chemicals, covering tablets, capsules, water injections, freeze-dried powder injections, granules, infusion preparations and other series of varieties. The chemicals produced by the company mainly include Shoubishan &; Reg indapamide sugar-coated tablets and other vascular drugs, adefovir tablets and other antiviral drugs, cefdinir and other antibacterial drugs. Li Sheng Pharmaceutical Co., Ltd. is the main subsidiary of Tianjin Pharmaceutical Co., Ltd. engaged in the production of chemical preparations. China Securities Regulatory Commission issued an announcement on February 28th, 2009, and the initial application of Tianjin Li Sheng Pharmaceutical Co., Ltd. was approved. Li Sheng Pharmaceutical intends to issue 46 million shares in Shenzhen Stock Exchange this time, with a total share capital of 65,438+82 million shares. The listing of Li Sheng Pharmaceutical will further enhance the company's capital strength and expand the market awareness of its products.
The company's chemical raw materials are small in scale, and its main products are GCLE and adefovir dipivoxil. However, due to the huge impact of the financial crisis in Europe, America and other countries and regions, the demand for chemical raw materials abroad has been greatly reduced, and the company's raw material exports have been greatly affected since 2008.
The company's pharmaceutical circulation business is mainly distributed in Tianjin and its surrounding areas. Due to its historical background and some pharmaceutical franchises, it has formed a certain monopoly advantage in the local area. The company is mainly involved in the field of pharmaceutical circulation through Taiping Group, Hongze Company, Tianjin Pharmaceutical Chain Company and Hebei Dezelong Company. These four companies have their own emphases in business. Taiping Group focuses on pure hospital sales, Hongze Company focuses on exclusive agency, Hebei Dezelong focuses on commercial deployment, and Tianjin pharmaceutical chain company focuses on pharmacy retail. The company's sales targets are mainly large hospitals, supplemented by chain pharmacies, drug wholesale stations and the third terminal market. The distribution network of the company's pharmaceutical circulation business in Tianjin covers 100% of tertiary hospitals and about 50% of secondary and tertiary hospitals. It is the most widely distributed pharmaceutical batch enterprise in Tianjin, and it has formed a certain monopoly advantage in the local area. In addition to strengthening the company's own drug sales, the company's drug circulation is also conducive to obtaining more medical resources. In the future, the company plans to integrate the pharmaceutical circulation enterprises with the sales departments of various production enterprises, so as to greatly increase the breadth and depth of the sales network and enhance the coordinated development of pharmaceutical production and pharmaceutical circulation. However, with the introduction of the new medical reform plan, the market competition environment is becoming increasingly fierce, and the company's pharmaceutical circulation plate will face the competition of pharmaceutical commercial wholesalers represented by Sinopharm Holdings, which will bring certain challenges to the company's pharmaceutical circulation enterprises. Tianjin has a strong research and development strength in medicine and pharmaceuticals. At present, it has the only national pharmaceutical research institute in China, 1 national enterprise technology center (Sino-Singapore pharmaceutical enterprise technology center) and 12 Tianjin municipal enterprise technology center. All affiliated enterprises have product and technology research and development institutions, which serve the product and technology development of enterprises and form a relatively complete scientific and technological development system for the company's new product development, production process improvement and product quality improvement.